Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

29

Revenue 2017

Soliris

The Top Pharma List's top 50 pharmaceutical products by global sales ranking is compiled from GlobalData's pharmaceutical revenue figures. Soliris was produced by Alexion.

The trials and tribulations of rare opportunities

The trials and tribulations of rare opportunities Those hoping to follow where Humira, Soliris and Fabrazyme led should be prepared for clinical development to be complex. ... Humira, the world’s best-selling drug, has multiple orphan designations. Likewise Soliris (eculizomab) – which generated

Orphan drugs and breakthrough therapies drive Cortellis Drugs to Watch 2019

Orphan drugs and breakthrough therapies drive Cortellis Drugs to Watch 2019 It is a next- generation follow-on to Soliris, Alexion’s current PNH blockbuster – also a humanised monoclonal antibody – with more convenient dosing.

CHMP nod for Alexion, GSK drugs, revocation for Lartruvo

CHMP nod for Alexion, GSK drugs, revocation for Lartruvo The CHMP recommended 13 medicines last Friday, including Ultomiris, Alexion’s follow-up to its rare disease blockbuster Soliris, and GSK’s single pill, two-drug HIV regimen, Dovato. ... A second-generation PNH therapy, Ultomiris has matched

Alnylam swaps Sanofi for Regeneron as R&D partner

Alnylam swaps Sanofi for Regeneron as R&D partner C5 is also targeted by Alexion’s Soliris (eculizumab) for paroxysmal nocturnal hemoglobinuria (PNH) and haemolytic uremic syndrome (HUS), which was a $2.56bn product last year.

Drug launches to watch in 2019

Drug launches to watch in 2019 Analysts predict peak sales of up to $3bn. 5. Ultomiris – Alexion’s follow-up to Soliris. ... The drug matched Soliris for efficacy with a trend towards superiority and has improved dosing.

[ Previous 5 results ] 1 2 3 4 5 6 7 8 9 [ Next 5 results ]

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Lucid Group Communications Limited

WE’RE ON A MISSION To enhance patients’ lives through communication that changes behaviour and improves patient health outcomes....

Latest intelligence

DEMAND DIVERSITY REPORT 01: Exploring attitudes towards clinical research among people from different ethnic groups in the UK
This report reveals insights from the people themselves, and discusses the starting points for overcoming current challenges....
Why are new medicinal products denied reimbursement in France?
Many medicinal products looking to launch are rejected for reimbursement in France. A manufacturer must convince the Transparency Committee that their product is safe, effective and offers added value relative...
OPEN Health attend EB World Congress—building on momentum and strength in numbers for epidermolysis bullosa
Ben Speller shares his thoughts on the value of disease specific congresses...

Infographics